• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康人群中 8 种主要肠道病毒中和抗体的血清学调查。

Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population.

机构信息

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.

Beijing Wantai Biological Pharmacy Enterprise, Beijing, 102206, China.

出版信息

Emerg Microbes Infect. 2018 Jan 10;7(1):2. doi: 10.1038/s41426-017-0003-z.

DOI:10.1038/s41426-017-0003-z
PMID:29323107
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5837151/
Abstract

Human enteroviruses (EVs) are the most common causative agents infecting human, causing many harmful diseases, such as hand, foot, and mouth disease (HFMD), herpangina (HA), myocarditis, encephalitis, and aseptic meningitis. EV-related diseases pose a serious worldwide threat to public health. To gain comprehensive insight into the seroepidemiology of major prevalent EVs in humans, we firstly performed a serological survey for neutralizing antibodies (nAbs) against Enterovirus A71 (EV-A71), Coxsackie virus A16 (CV-A16), Coxsackie virus A6 (CV-A6), Coxsackie virus A10 (CV-A10), Coxsackie virus B3 (CV-B3), Coxsackie virus B5 (CV-B5), Echovirus 25 (ECHO25), and Echovirus 30 (ECHO30) among the healthy population in Xiamen City in 2016, using micro-neutralization assay. A total of 515 subjects aged 5 months to 83 years were recruited by stratified random sampling. Most major human EVs are widely circulated in Xiamen City and usually infect infants and children. The overall seroprevalence of these eight EVs were ranged from 14.4% to 42.7%, and most of them increased with age and subsequently reached a plateau. The co-existence of nAbs against various EVs are common among people ≥ 7 years of age, due to the alternate infections or co-infections with different serotypes of EVs, while most children were negative for nAb against EVs, especially those < 1 year of age. This is the first report detailing the seroepidemiology of eight prevalent EVs in the same population, which provides scientific data supporting further studies on the improvement of EV-related disease prevention and control.

摘要

人类肠道病毒(EVs)是感染人类的最常见病原体,可导致多种有害疾病,如手足口病(HFMD)、疱疹性咽峡炎(HA)、心肌炎、脑炎和无菌性脑膜炎。EV 相关疾病对全球公共卫生构成严重威胁。为了全面了解人类主要流行 EV 的血清流行病学,我们首先使用微量中和试验对 2016 年厦门市健康人群中针对肠道病毒 A71(EV-A71)、柯萨奇病毒 A16(CV-A16)、柯萨奇病毒 A6(CV-A6)、柯萨奇病毒 A10(CV-A10)、柯萨奇病毒 B3(CV-B3)、柯萨奇病毒 B5(CV-B5)、埃可病毒 25(ECHO25)和埃可病毒 30(ECHO30)的中和抗体(nAbs)进行了血清学调查。通过分层随机抽样共招募了 515 名 5 个月至 83 岁的受试者。厦门市大多数主要的人类 EV 广泛传播,通常感染婴儿和儿童。这 8 种 EV 的总体血清阳性率在 14.4%至 42.7%之间,大多数随着年龄的增长而增加,并随后达到稳定水平。由于交替感染或混合感染不同血清型的 EV,年龄≥7 岁的人群中存在针对多种 EV 的 nAbs 共存,而大多数儿童对 EV 的 nAb 呈阴性,尤其是年龄<1 岁的儿童。这是首次详细报告同一人群中 8 种流行 EV 的血清流行病学情况,为进一步开展 EV 相关疾病预防和控制研究提供了科学数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6ee/5837151/5937995556a5/41426_2017_3_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6ee/5837151/75f16bec4052/41426_2017_3_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6ee/5837151/40c1fc191b76/41426_2017_3_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6ee/5837151/5937995556a5/41426_2017_3_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6ee/5837151/75f16bec4052/41426_2017_3_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6ee/5837151/40c1fc191b76/41426_2017_3_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6ee/5837151/5937995556a5/41426_2017_3_Fig3_HTML.jpg

相似文献

1
Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population.健康人群中 8 种主要肠道病毒中和抗体的血清学调查。
Emerg Microbes Infect. 2018 Jan 10;7(1):2. doi: 10.1038/s41426-017-0003-z.
2
EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.EV-A71 疫苗上市许可:多价肠道病毒疫苗控制手足口病和其他严重疾病的第一步。
Emerg Microbes Infect. 2016 Jul 20;5(7):e75. doi: 10.1038/emi.2016.73.
3
The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.中国昆明使用肠道病毒 71 型灭活疫苗前后肠道病毒感染的流行病学特征。
Emerg Microbes Infect. 2021 Dec;10(1):619-628. doi: 10.1080/22221751.2021.1899772.
4
Seroprevalence of Enterovirus A71 and Coxsackievirus A16 in Healthy People in Shandong Province, China.中国山东省健康人群中肠道病毒A71型和柯萨奇病毒A16型的血清流行率
PLoS One. 2016 Sep 9;11(9):e0162373. doi: 10.1371/journal.pone.0162373. eCollection 2016.
5
Is a multivalent hand, foot, and mouth disease vaccine feasible?多价手足口病疫苗是否可行?
Hum Vaccin Immunother. 2015;11(11):2688-704. doi: 10.1080/21645515.2015.1049780. Epub 2015 May 26.
6
Epidemiological and etiological characteristics of herpangina and hand foot mouth diseases in Jiangsu, China, 2013-2014.2013 - 2014年中国江苏省疱疹性咽峡炎和手足口病的流行病学及病因学特征
Hum Vaccin Immunother. 2017 Apr 3;13(4):823-830. doi: 10.1080/21645515.2016.1236879. Epub 2016 Oct 21.
7
Seroepidemiology of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus 71 Infections among Children and Adolescents in Singapore, 2008-2010.2008 - 2010年新加坡儿童和青少年中柯萨奇病毒A6、柯萨奇病毒A16和肠道病毒71感染的血清流行病学研究
PLoS One. 2015 May 26;10(5):e0127999. doi: 10.1371/journal.pone.0127999. eCollection 2015.
8
Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.柯萨奇病毒 A6 和 A10 病毒粒子的免疫学和生化特性。
Antiviral Res. 2016 May;129:58-66. doi: 10.1016/j.antiviral.2016.02.008. Epub 2016 Feb 17.
9
[Clinical analysis of 555 outpatients with hand, foot and mouth diseases caused by different enteroviruses].[555例不同肠道病毒所致手足口病门诊病例临床分析]
Zhonghua Er Ke Za Zhi. 2019 Jun 2;57(6):445-451. doi: 10.3760/cma.j.issn.0578-1310.2019.06.009.
10
Incidence of Infection of Enterovirus 71 and Coxsackieviruses A6 and A16 among Household Contacts of Index Cases in Dong Thap Province, Southern Vietnam.越南南部同塔省手足口病患者家庭接触者中肠道病毒 71 型和柯萨奇病毒 A6、A16 的感染发生率。
Biomed Res Int. 2020 Nov 19;2020:9850351. doi: 10.1155/2020/9850351. eCollection 2020.

引用本文的文献

1
Epidemiological, etiological, and serological characteristics of hand, foot, and mouth disease in Guizhou Province, Southwest China, from 2008 to 2023.2008年至2023年中国西南部贵州省手足口病的流行病学、病因学及血清学特征
PLoS Negl Trop Dis. 2025 Aug 18;19(8):e0013394. doi: 10.1371/journal.pntd.0013394. eCollection 2025 Aug.
2
Clinical characteristics of fatal cases of hand, foot and mouth disease in children.儿童手足口病死亡病例的临床特征
Front Pediatr. 2025 Jul 17;13:1522164. doi: 10.3389/fped.2025.1522164. eCollection 2025.
3
Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019-2021.

本文引用的文献

1
Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody.柯萨奇病毒 A6 及其与中和抗体复合物的原子结构。
Nat Commun. 2017 Sep 11;8(1):505. doi: 10.1038/s41467-017-00477-9.
2
A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation.用于抗病毒评估的柯萨奇病毒 A10 感染新生鼠模型。
Antiviral Res. 2017 Aug;144:247-255. doi: 10.1016/j.antiviral.2017.06.008. Epub 2017 Jun 15.
3
Epidemics and aetiology of hand, foot and mouth disease in Xiamen, China, from 2008 to 2015.2008年至2015年中国厦门手足口病的流行情况及病因学
2019 - 2021年中国广州肠道病毒A71型血清流行率
Biosaf Health. 2023 May 6;5(3):168-173. doi: 10.1016/j.bsheal.2023.05.002. eCollection 2023 Jun.
4
Serology supportive of recent coxsackievirus B infection is correlated with multisystem inflammatory syndrome in children (MIS-C).支持近期柯萨奇病毒B感染的血清学与儿童多系统炎症综合征(MIS-C)相关。
Microbiol Spectr. 2025 Mar 4;13(3):e0174124. doi: 10.1128/spectrum.01741-24. Epub 2025 Feb 5.
5
Seroprevalence of neutralizing antibodies against HFMD associated enteroviruses among healthy individuals in Shanghai, China, 2022.2022 年中国上海健康人群中针对手足口病相关肠病毒的中和抗体血清阳性率。
Virol Sin. 2024 Aug;39(4):694-698. doi: 10.1016/j.virs.2024.05.008. Epub 2024 May 25.
6
Molecular Amplification and Cell Culturing Efficiency for Enteroviruses' Detection in Cerebrospinal Fluids of Algerian Patients Suffering from Meningitis.分子扩增和细胞培养效率在阿尔及利亚脑膜炎患者脑脊液中肠道病毒检测的应用。
Viruses. 2024 Jan 23;16(2):170. doi: 10.3390/v16020170.
7
Seasonal Testing, Results, and Effect of the Pandemic on Coxsackievirus Serum Studies.季节性检测、结果以及大流行对柯萨奇病毒血清学研究的影响。
Microorganisms. 2024 Feb 10;12(2):367. doi: 10.3390/microorganisms12020367.
8
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors.利用柯萨奇病毒 B5 和协同的 DNA 损伤反应抑制剂进行非小细胞肺癌(NSCLC)溶瘤治疗。
Signal Transduct Target Ther. 2023 Sep 25;8(1):366. doi: 10.1038/s41392-023-01603-4.
9
Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms.长期大剂量免疫球蛋白成功治疗有肺部、神经和心脏症状的长新冠患者。
Front Immunol. 2023 Feb 2;13:1033651. doi: 10.3389/fimmu.2022.1033651. eCollection 2022.
10
Seroprevalence of coxsackievirus A6 and enterovirus A71 infection in humans: a systematic review and meta-analysis.柯萨奇病毒 A6 和肠道病毒 A71 感染在人类中的血清流行率:系统评价和荟萃分析。
Arch Virol. 2023 Jan 7;168(2):37. doi: 10.1007/s00705-022-05642-0.
Epidemiol Infect. 2017 Jul;145(9):1865-1874. doi: 10.1017/S0950268817000309. Epub 2017 Apr 3.
4
A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.一种新型肠道病毒71型灭活疫苗可在小鼠体内引发针对柯萨奇病毒A16的交叉保护性免疫。
Vaccine. 2016 Nov 21;34(48):5938-5945. doi: 10.1016/j.vaccine.2016.10.018. Epub 2016 Oct 19.
5
A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6.用于评估抗柯萨奇病毒A6抗体和疫苗的新生小鼠模型。
Antiviral Res. 2016 Oct;134:50-57. doi: 10.1016/j.antiviral.2016.08.025. Epub 2016 Aug 28.
6
Seroepidemiology of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus 71 infections in infants and children: A prospective cohort study in Jiangsu, China.中国江苏婴幼儿和儿童柯萨奇病毒A6、柯萨奇病毒A16和肠道病毒71感染的血清流行病学:一项前瞻性队列研究
J Infect. 2016 Nov;73(5):509-512. doi: 10.1016/j.jinf.2016.08.008. Epub 2016 Aug 19.
7
Prediction of Protection against Asian Enterovirus 71 Outbreak Strains by Cross-neutralizing Capacity of Serum from Dutch Donors, The Netherlands.荷兰捐赠者血清的交叉中和能力对亚洲肠道病毒71型暴发菌株的保护作用预测,荷兰
Emerg Infect Dis. 2016 Sep;22(9):1562-9. doi: 10.3201/eid2209.151579.
8
EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.EV-A71 疫苗上市许可:多价肠道病毒疫苗控制手足口病和其他严重疾病的第一步。
Emerg Microbes Infect. 2016 Jul 20;5(7):e75. doi: 10.1038/emi.2016.73.
9
Characterization of Coxsackievirus A6- and Enterovirus 71-Associated Hand Foot and Mouth Disease in Beijing, China, from 2013 to 2015.2013年至2015年中国北京柯萨奇病毒A6型和肠道病毒71型相关手足口病的特征分析
Front Microbiol. 2016 Mar 30;7:391. doi: 10.3389/fmicb.2016.00391. eCollection 2016.
10
Seroepidemiology of Human Enterovirus 71 Infection among Children, Cambodia.柬埔寨儿童肠道病毒71型感染的血清流行病学研究
Emerg Infect Dis. 2016 Jan;22(1):92-5. doi: 10.3201/eid2201.151323.